2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 285

Inflammatory Bowel Disease Is Associated with a Substantial Economic Burden in Patients with Psoriatic Arthritis and in Patients with Ankylosing Spondylitis
Abstract Number: 318

Inflammatory Findings Detected By MRI at Entheseal Sites in the Pelvic Girdle of Patients with Polymyalgia Rheumatica Have Potential for a Diagnostic Test
Abstract Number: 812

Inflammatory Stays Inflammatory: A Subgroup of Systemic Sclerosis Characterized By High Morbidity and Inflammatory Resistance to Cyclophosphamide
Abstract Number: 216

Inflectra and Remicade Use and Cost in Canada Under Provincial Drug Plans in 2016
Abstract Number: 2269

Infliximab Therapy in Refractory Retinal Vasculitis of Behçet’s Disease, Short and Long-Term Follow-up. Multicenter Study of 72 Patients
Abstract Number: 1617

Influence of Disease Activity in the Physical Activity of Psoriatic Arthritis Patients
Abstract Number: 1269

Influence of Diuretic-Response Sodium Transporter Genes on Renal Uric Acid Handling in Response to Frusemide
Abstract Number: 611

Influence of Dose Titration of Concomitant Steroid and Methotrexate during Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice Based on the IORRA Cohort
Abstract Number: 644

Influence of Inflammation and Structural Damage on Global Functioning in Patients with Axial Spondyloarthritis – Using the ASAS Health Index in Routine Care
Abstract Number: 1282

Influence of Renal Function on the Velocity of Tophus Resolution and Achievement of Disease Remission in Patients with Chronic Refractory Gout Treated with Pegloticase
Abstract Number: 1875

Influence of Setting an Upper Limit of the Modified Rodnan Skin Score As an Inclusion Criterion in Systemic Sclerosis Clinical Trials on the Ratio of Skin Fibrosis Progression Vs. Improvement – an Analysis of the Genisos Cohort
Abstract Number: 2502

Influence of the Treatment with Biologic Agents in the Viremia By the Endogenous Anelovirus Torque Teno Virus in Patients with Chronic Arthritis
Abstract Number: 1010

Inhibition of Bruton’s Tyrosine Kinase (BTK) Prevents Inflammatory Macrophage Differentiation: A Potential Role in RA and SLE
Abstract Number: 140

Inhibition of Cathepsin S Leads to Suppression of SS-a/SS-B Specific T Cells from Patients with Primary Sjøgren Syndrome
Abstract Number: 1012

Inhibition of Inflammation and Oxidative Stress in Systemic Sclerosis (SSc) Macrophages

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].